Back to search
FDAFDA · Food and drugs·Recall number D-1051-2019

Losartan Potassium Tablets, USP, 50 mg, a) 30-count bottle (NDC: 68788-0048-03), b) 90-count bottle (NDC: 68788-0048-09), Rx Only, Mfg: Torrent Pharma Inc. Basking Ridge, NJ. Relabeled by: Preferred Pharmaceuticals, Inc. 1250 N. Lakeview Ave., Suite O, Anaheim, CA 92807.

Published March 27, 2019 · Recall initiated: March 6, 2019

Summary

FDA records drug Class II recall D-1051-2019, published March 27, 2019 and initiated March 6, 2019. Recalling firm: Preferred Pharmaceuticals, Inc; Status: Terminated; Reported quantity: 530; Lot: Count, lots, expiry: a) 30-count bottle C2218C, exp 9/2020, D1318E, exp 10/2020; b) 90-count bottle C2719J, exp 9/2020, E1818B, exp 10/2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified.

What to do

Voluntary: Firm initiated · Telephone

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Preferred Pharmaceuticals, Inc
Distributor
California, Georgia, Indiana
Lot
Count, lots, expiry: a) 30-count bottle C2218C, exp 9/2020, D1318E, exp 10/2020; b) 90-count bottle C2719J, exp 9/2020, E1818B, exp 10/2020.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Losartan Potassium Tablets, USP, 50 mg, a) 30-count bottle (NDC: 68788-0048-03), b) 90-count bottle (NDC: 68788-0048-09), Rx Only, Mfg: Torrent Pharma Inc. Basking Ridge, NJ. Relabeled by: Preferred Pharmaceuticals, Inc. 1250 N. Lakeview Ave., Suite O, Anaheim, CA 92807. recalled?

Yes. FDA published recall D-1051-2019 on March 27, 2019. Reported hazard: CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified.

What should I do if I have this product?

Voluntary: Firm initiated · Telephone